Skip to main content

Table 3 Anti-relapse efficacy of a total tafenoquine dose 1.8 mg/kg (0.6 mg/kg/day for three days or 1.8 mg/kg once) monotherapy or in combination with chloroquine and other blood stage regimens.

From: Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)

Treatment Cohort Notes of clarification Outcome
#cured/total (%)
TQ Alone*   
Cohort 3 TQ given alone after quinine pretreatment 6/6 (100)
TQ + CQ 16   
Cohort 1** CQ given sequentially after blood stage failure of first tafenoquine treatment regimen 2/2 (100)
Cohort 2 CQ + TQ given simultaneously for first treatment 2/2 (100)
TQ + CQ 24   
Cohort 1 CQ given sequentially after blood stage failure of first relapse treatment 2/2 (100)
Cohort 1 Treatment of second relapse 1/2 (50)
Cohort 2 CQ + TQ given simultaneously for first treatment 5/5 (100)
Cohort 3 TQ given with CQ after quinine pretreatment to eliminate blood stage parasites 6/6 (100)
Unpublished data TQ given as a single dose for first treatment (data not shown) 2/2 (100)
TQ + Other Anti-malarials   
Cohort 2 Simultaneous combination with artemether-lumefantrine for initial treatment 5/6 (83)
Unpublished data Simultaneous combination with atovaquone-proguanil for initial treatment (data not shown) 2/2 (100)
Total   
Tafenoquine alone   6/6 (100)
TQ + CQ   20/21 (95)
TQ + all BS**All   27/29 (93)
TQ   33/35 (94)
  1. * This refers to published data in which blood stage parasites were eliminated prior to tafenoquine or tafenoquine/chloroquine treatment. ** These are monkeys (Table 1) which were treated with chloroquine after tafenoquine monotherapy failed to clear blood stage parasites. For the purposes of the anti-relapse endpoint, these monkeys were considered to have been given a combination regimen. ** All blood schizonticidal drugs.